Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 26:13:1224528.
doi: 10.3389/fonc.2023.1224528. eCollection 2023.

Editorial: Novel targeted drugs for indolent lymphoid malignancies

Tadeusz Robak  1   2 , Bartosz Puła  3 , Iwona Hus  4
Affiliations
Editorial

Editorial: Novel targeted drugs for indolent lymphoid malignancies

Tadeusz Robak et al. Front Oncol. .
No abstract available

Keywords: BRAF inhibitors; BTK inhibitors; CAR T; cellular therapies; follicular lymphoma; hairy cell leukemia; marginal zone lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Targeted drugs and their targets for indolent B-cell lymphoid malignancies.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic Novel targeted drugs for indolent lymphoid malignancies

References

    1. Falini B, Martino G, Lazzi S. A comparison of the international consensus and 5th world health organization classifications of mature b-cell lymphomas. Leukemia (2023) 37(1):18–34. doi: 10.1038/s41375-022-01764-1 - DOI - PMC - PubMed
    1. Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting bruton’s tyrosine kinase in cancers: drug development advances. Leukemia (2021) v35(2):v312–332. doi: 10.1038/s41375-020-01072-6 - DOI - PMC - PubMed
    1. Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov (2021) 20(10):741–69. doi: 10.1038/s41573-021-00209 - DOI - PMC - PubMed
    1. Lew TE, Seymour JF. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. J Hematol Oncol (2022) 15(1):75. doi: 10.1186/s13045-022-01295-3 - DOI - PMC - PubMed
    1. Mohty R, Kharfan-Dabaja MA. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. Ther Adv Hematol (2022) 13:20406207221142133. doi: 10.1177/20406207221142133 - DOI - PMC - PubMed

Publication types